Rocket One Inc. (RKTO) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Rocket One Inc. (NASDAQ: RKTO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.49 (-5.60% 1D, market cap $12.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RKTO ranks #539 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RKTO carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LPCN (Lipocine Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, RKTO leads on earnings multiple (N/A) while RKTO leads on capital efficiency (-35.0% ROIC).
Per RKTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711786), Rocket One Inc. generated $0 in revenue, -$12.5M in net income, and -$9.8M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While RKTO currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.51) forces dealer call-delta covering toward $2.57.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Rocket One Inc. (RKTO) dropped -5.60% to $0.49, trading at 2% of its 52-week range ($0.47 – $2.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RKTO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RKTO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Rocket One Inc. (RKTO) ranks #539 by composite RQD confidence (40/100, grade D-) and #871 by equity capitalization ($12.8M). Within this direct 5-issuer industry benchmark cohort, RKTO leads on earnings valuation at N/A trailing P/E, while RKTO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RKTO currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RKTO
ACTIVE
Rocket One Inc. | D- | 40/100 | — | — | -35.0% | -5.60% | $12.8M | Benchmark Subject |
| LPCN Lipocine Inc. | E | 23/100 | — | — | -35.0% | -5.26% | $12.5M | /lpcn-vs-rkto → |
| KTTA Pasithea Therapeutics Corp. | D- | 40/100 | — | — | -35.0% | +0.16% | $12.3M | /ktta-vs-rkto → |
| DARE Dare Bioscience Inc. | D- | 36/100 | — | 71.3% | -35.0% | +2.66% | $13.4M | /dare-vs-rkto → |
| HIND Vyome Holdings Inc. | E | 29/100 | — | 68.4% | -35.0% | +2.86% | $12.3M | /hind-vs-rkto → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rocket One Inc. (RKTO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.5M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (-40.5% YoY). On the balance sheet, RKTO closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$12.5M | -$9.8M | -$9.8M | $7.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$8.2M | -$7.0M | -$7.0M | $7.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.1M | -$8.4M | -$8.4M | — | — |
As of 2026-11-02, Rocket One Inc. (NASDAQ: RKTO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.49 (-5.60% 1D, market cap $12.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RKTO ranks #539 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RKTO carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LPCN (Lipocine Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, RKTO leads on earnings multiple (N/A) while RKTO leads on capital efficiency (-35.0% ROIC).
Per RKTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711786), Rocket One Inc. generated $0 in revenue, -$12.5M in net income, and -$9.8M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RKTO last traded at $0.49 (-5.60% on volume of 331,369 shares), positioning the stock -25.76% below its 50-day simple moving average ($0.66) and -42.35% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.47 to $2.45, RKTO sits at the 1.0% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.55).
Why RKTO Stock dropped -5.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, RKTO scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Taken together, a prospective investor evaluating RKTO today faces a stock with negative returns on capital, no free cash flow yield, weak insider signals, and a below-midpoint institutional picture. Any upside case would need to rest on catalysts and on the company's ability to change its cash generation trajectory, which the source data does not show as yet. Valuation tradeoffs are difficult to frame because the P/E and EV/EBITDA metrics are not available in source data.
Rocket One Inc. (RKTO) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the company's market capitalization is $0.0B. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the three periods shown, so the source data does not identify a commercial revenue stream. Per the recent news wire, the company has announced agreements related to drone-capture technology, AI chip development, and magnetic memory research, but the source data does not establish how these relate to revenue.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-12.4M | $-12.5M | N/A | $-9.8M | $6.2M | N/A |
| FY 2024 | $0.0M | $-8.2M | $-8.2M | N/A | $-7.0M | $7.0M | N/A |
| FY 2023 | $0.0M | $-8.0M | $-8.1M | N/A | $-8.4M | N/A | N/A |
Per the SEC financials, the company reported operating losses in each period shown, with FY 2025 operating loss widening to $-12.4M from $-8.2M in FY 2024. Per the Roarable RQD rating, ROIC is -35%, and the company's gross, operating, and net margins are each listed as 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with a Debt/Equity ratio of 0.5. Cash declined from $7.0M in FY 2024 to $6.2M in FY 2025 per the SEC financials, and debt is listed as N/A in every period.
Per the recent news wire, the company's most recent items concern a patent license agreement with the U.S. Air Force for technology designed to capture and neutralize hostile drones, an agreement to advance nanomagnetic AI chip technology and device prototyping, an AI chip development agreement with Virginia Commonwealth University targeting ultra-low-power magnetic computing, and a partnership with VCU to advance SKYMRAM magnetic memory technology. The one item rated GREEN, the most favorable light, is the VCU SKYMRAM partnership, labeled CATALYST; the remaining items are rated YELLOW and labeled MARKET WIRE.
Per the recent news wire, one item flags a risk watch: a report that the stock faces a reverse-split vote and a dilution proposal. Because the company's market price is $0.52 and its 52-week range low is $0.47, a reverse split and dilution are relevant risk items for a prospective investor to track. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations. For a prospective investor, the relevant second-order question is whether the technology partnerships in the news wire (defense, AI chip, and magnetic memory) would generate commercial counterparties that the source data does not yet identify. The reverse-split and dilution risk flagged in the news wire is a second-order ripple that could affect per-share economics regardless of supply-chain position.
Real-time company headlines, analyst actions, and sector developments for Rocket One Inc. (RKTO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Rocket One Inc. (RKTO) market action, institutional positioning, and fundamental catalysts.
Welcome to the RKTO (Rocket One Inc.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on RKTO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Rocket One Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on RKTO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.52 (52-wk range $0.47 - $2.45), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).